It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
We previously confirmed that a strain of Lactobacillus oris isolated from the fecal samples of healthy Hainan centenarian having potent lipid-lowering ability in HepG2 cells; and this study was to investigate the effect of the stain on non-alcoholic fatty liver in mice in vivio. The Lactobacillus oris strain isolated from Hainan centenarian fecal samples were frozen stored in our laboratory. Thirty ob/ob mice (10 in each group) were orally gavaged with Lactobacillus oris (Lactobacillus, 5 × 109 cfu), mixed probiotics (Mixed, 5 × 109 cfu, a mixture with known lipid-lowering ability), or culture medium (Control) respectively. Lactobacillus oris isolated from fecal samples of Hainan centenarians showed significantly in vivo lipid lowering ability compared with the controls, and the ability was comparable with mixed probiotics strains in mice The possible mechanisms of lipid-lowering of probiotics and Lactobacillus oris may be associated with HMGR inhibition to suppress the synthesis of endogenous cholesterol; bile acids reabsorption, and intestinal FXR-FGF15 signaling pathways promoting the cholesterol conversion into bile acids secretion.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Hainan Hospital of PLA General Hospital, Department of Gastroenterology and Hepatology, Sanya, China
2 Second Medical Center of PLA General Hospital, Sixth Health Care Department, Beijing, China (GRID:grid.414252.4) (ISNI:0000 0004 1761 8894)
3 First Medical Center of PLA General Hospital, Department of Gastroenterology and Hepatology, Beijing, China (GRID:grid.414252.4) (ISNI:0000 0004 1761 8894)
4 Unit 91917, Beijing, China (GRID:grid.414252.4)
5 Tianjin First Central Hospital, Emergency Department, Tianjin, China (GRID:grid.417024.4) (ISNI:0000 0004 0605 6814)
6 Chinese Academy of Medical Sciences and Peking Union Medical College, Institute of Medicinal Plant Development, Beijing, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839)
7 Hainan Hospital of PLA General Hospital, Department of Gastroenterology and Hepatology, Sanya, China (GRID:grid.417024.4)
8 Beijing QuantiHealth Technology Co., Ltd., Beijing, China (GRID:grid.414252.4)